Yes, I expected this as a result of layoffs, including not just numbers of staff, but lots of institutional knowledge and expertise lost. This is a reality despite any promising new attitudes about accelerated approvals, cell therapies, etc. You can't just spin this bureaucracy on a dime...
Still expect great outcomes for us in the long run.
Meanwhile, if anyone wants to see an article on this delay without a paywall:
https://www.fiercebiotech.com/biotech/fdas-heavy-workload-blamed-delays-kalvistas-angioedema-drug-approval-decision
Yes, I expected this as a result of layoffs, including not just...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.80 |
Change
-0.030(1.64%) |
Mkt cap ! $2.306B | |||
| Open | High | Low | Value | Volume |
| $1.80 | $1.83 | $1.76 | $11.26M | 6.310M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1202 | $1.94 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.62 | 9592 | 3 |
View Market Depth
| Last trade - 15.59pm 18/06/2025 (20 minute delay) ? |
| MSB (ASX) Chart |